Literature DB >> 32531427

Delirium as a presenting feature in COVID-19: Neuroinvasive infection or autoimmune encephalopathy?

Akram A Hosseini1, Ashit K Shetty2, Nikola Sprigg3, Dorothee P Auer4, Cris S Constantinescu5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32531427      PMCID: PMC7282789          DOI: 10.1016/j.bbi.2020.06.012

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   19.227


× No keyword cloud information.
Letter to the Editor The most common symptoms of COVID-19 are related to systemic and respiratory involvement. (Mao et al., 2019) We report two cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection with acute onset of altered mental status and delirium with normal respiration and metabolic balance in the first 48 h. Informed consent for publication was obtained from both patients.

Case 1

A 46-year-old male presented with two days history of headache followed by acute hypoactive delirium, disinhibition, confusion, but no fever, cough, or systemic manifestations. He had no previous medical or psychiatric illness, smoking, alcohol or illicit drug use. He was apyrexic but encephalopathic, nonverbal, and unable to follow commands. There was no weakness, but he had ankle clonus, brisk reflexes and Babinski’s sign. Baseline brain CT and blood tests were unremarkable (Table 1 ). Nasopharyngeal swab real-time reverse-transcriptase–polymerase-chain-reaction (rRT-PCR) test was positive for SARS-CoV2.
Table 1

Patient data at the time of presentation to hospital and ≥48 h after the onset of altered mental status.

Value (normal range)Case 1
Case 2
at presentation48 h lateraat presentation60 h latera
Body temperature, °C36.738.336.938.4
Pulse rate, beats/minute86909182
Blood pressure, mmHg116/74142/75185/93147/81
Oxygen saturation on air97%100%99%88%
Hemoglobin, g/L (130–180)14713713297
White cell count, × 109/L (4–11)7.129.26.369.65
Neutrophil count, × 109/L (2–7)3.67.975.838.68
Lymphocyte count, × 109/L (1–4)2.820.560.390.38
Platelet count, × 109/L (150–450)133132313232
C-Reactive Protein, mg/L (0–10)<5<5<512
D-Dimer, ug/L (0–500)Up to 1659bUp to 3748b
Alanine transaminase, U/L (0–35)15Up to 165b12145
Sodium, mmol/L (134–145)133136134115
Urea, mmol/L (2–6.5)3.28.85.85.1
Creatinine, umol/L (59–104)88996553
Serum osmolality, mosmol/kg (275–295)257
Urine osmolality, mosmol/kg (50–1200)664
Serum glucose mmol/L (3–7.8)8.75.88.15.4
CSF glucose, mmol/L (~60 to 80% of serum value)4.54.1
CSF opening pressure, cmH2O1813
CSF white cell × 109/L (0)00
CSF protein, mg/L (150–450)987340
CSF oligoclonal bandsPositiveNot found
Serum oligoclonal bandsPositiveNot found
CSF PCR for SARS-CoV2NegativeNegative
CSF PCR for Herpes Simplex 1 and 2, Varicella zoster, enterovirusesNegativeNegative
Antibodies against NMDAR, LGi1, CASPR2, GABA-B, AMPA in serum and CSFNot detectedNot detected
Paraneoplastic anti-neuronal antibodies in serum and CSFcNot detectedNot detected
Antiphospholipid antibodiesNegative
Thrombophilia screenNormal
Thrombin Time, seconds (14–19)16.633.9
APTT, seconds (21–29)20.854.2
Serum alpha-galactosidase A, pmol/punch/h (6.3–47)26.1
12-lead electrocardiogramsinus rhythmsinus rhythmsinus rhythmsinus rhythm

CSF, cerebrospinal fluid; NMDAR, N-methyl-D-aspartate receptor; LGi1, leucine-rich glioma inactivated 1; CASPR2, contactin-associated protein 2; GABA-B, γ-Aminobutyric acid-B receptor; AMPA, GluR1 and GluR2 subunits of the AMPA receptor; APTT: activated partial prothrombin time.

After the onset of altered mental state.

The highest level measured between day 6 and day 8.

Paraneoplastic antibodies included anti-Hu, anti-Yo, anti-Ri, and anti-amphiphysin.

Patient data at the time of presentation to hospital and ≥48 h after the onset of altered mental status. CSF, cerebrospinal fluid; NMDAR, N-methyl-D-aspartate receptor; LGi1, leucine-rich glioma inactivated 1; CASPR2, contactin-associated protein 2; GABA-B, γ-Aminobutyric acid-B receptor; AMPA, GluR1 and GluR2 subunits of the AMPA receptor; APTT: activated partial prothrombin time. After the onset of altered mental state. The highest level measured between day 6 and day 8. Paraneoplastic antibodies included anti-Hu, anti-Yo, anti-Ri, and anti-amphiphysin. After 2 days, he developed fever and status epilepticus requiring sedation, neuromuscular blockade and intubation. The fraction of inspired oxygen (FiO2) remained at 21% and no additional respiratory support was needed. Chest X-ray only showed patchy consolidation without significant progression on subsequent imaging. Cerebrospinal fluid (CSF) showed mildly raised protein and oligoclonal bands, and was negative for SARS-CoV2. Neuromuscular blockade was withdrawn on day 5, when the new symptom of cough emerged. Despite normal brain CT at 48 h, MRI on day 6 showed three hyperintense foci on diffusion-weighted images, but no overt restriction, consistent with T2-shine-through suggesting cellular infiltration/inflammation or small infarcts (Fig. 1 ). The presistent diffusion-weighted hyperintensity on subsequent MRI supported neuroinflammation. Cranial arteries were normal on CT angiogram. Empirical treatment included Ceftriaxone, Aciclovir and Sodium Valproate.
Fig. 1

Case 1, MRI head 6 days after the onset of delirium: white arrows show the signal hyperintensity changes in the subcortex of the left lateral temporal lobe on T2-Weighted (A), FLAIR (B), and Diffusion Weighted Image (C), and ADC map (D).

Case 1, MRI head 6 days after the onset of delirium: white arrows show the signal hyperintensity changes in the subcortex of the left lateral temporal lobe on T2-Weighted (A), FLAIR (B), and Diffusion Weighted Image (C), and ADC map (D). He noted hyposmia and dysgeusia during the convolescence. Despite improvement after a week, he had impairements in verbal fluecy, linguistic abstraction, phrase repetition, and delayed recall memory. He scored 20/30 on Montreal Cognitive Assessment on day 8.

Case 2

A 79-year-old female was admitted to hospital following a seizure resulting in injuries to her face. According to her relatives, the symptoms started a few hours earlier with confusion and verbal communication difficulties. There was no preceding illness. She had no fever, cough, or respiratory symptoms at presentation. Vital signs were normal. There were no sensory or motor deficits. She had dysphasia and impaired orientation, attention and memory. The first brain MRI only showed chronic small vessel ischemic changes. Chest CT scan only demonstrated bilateral pleural effusion. After 60 h, she had two generalized seizures, followed by fever and low oxygen saturation. Neurological examination confirmed poor mental state, with Glasgow Coma Scale scores between 8 and 13. Repeat blood tests showed hyponatremia. The second nasopharyngeal sample rRT-PCR was positive for SARS-CoV2. CSF revealed normal constituents (Table 1). CT scan and repeat brain MRI showed new changes in the limbic system with partial diffusion restriction, suggestive of limbic encephalitis (Fig. 2 ). Treatment included Levetiracetam and sodium correction.
Fig. 2

Case 2, MRI head 12 days after the onset of altered mental state: white arrows show the signal hyperintensity changes in the limbic system, predominantly in the left amygdala and hippocampus on FLAIR (A), partial restricted diffusion (B, C) and T1 hypointensity on post-Gadolinium-enhanced T1-weighted image (D).

Case 2, MRI head 12 days after the onset of altered mental state: white arrows show the signal hyperintensity changes in the limbic system, predominantly in the left amygdala and hippocampus on FLAIR (A), partial restricted diffusion (B, C) and T1 hypointensity on post-Gadolinium-enhanced T1-weighted image (D). The patient’s persistent delirium improved over 10 days with mild respiratory symptoms, hyposmia and dysgeusia. On day 15, she scored 19/30 on Montreal Cognitive Assessment with impaired verbal fluency, repetition, abstraction, and delayed recall memory.

Discussion

There is emerging evidence that SARS-CoV2 can present with neurological features and concomitant encephalopathy (Mao et al., 2019, Moriguchi et al., 2020). However, there is currently no report of limbic encephalitis associated with COVID-19 that is presented with delirium in the absence of respiratory, metabolic or systemic features, while these patients may be hidden sources of spreading the virus in busy clinical settings. The detection of SARS-CoV2 in the CSF in a patient with meningo-encephalitis supports neurotropic and neuroinvasive potential of the virus (Moriguchi et al., 2020) presumably through the blood vessel-rich meninges once the blood brain barrier is damaged (Baig et al., 2020). The evidence of SARS-CoV2 viral particles in brain capillary endothelial cells of an infected patient suggests hematogenous CNS entry (Paniz‐Mondolfi et al., 2020). The olfactory neuronal pathway could explain hyposmia (Desforges et al., 2019). Angiotensin-converting enzyme 2 (ACE2) receptors of vascular endothelium in respiratory system and meningeal capillaries can be the binding target for SARS-CoV2 proteins (Hamming et al., 2004). In the absence of detectable virus in the CSF, it is plausible that SARS-CoV2 causes an immunologic response that results in parenchymal inflammatory injury, cerebral edema and clinical manifestations of encephalopathy (Wu et al., 2020). The presence of oligoclonal bands in one of our patient’s CSF and serum supports immune-mediated response that is not restricted to intrathecal production of immunoglobulins. Increased interleukin-6 in severe SARS-Cov2 disease highlights the occurrence of immunologic response and indicates intracranial cytokine storms (Mehta et al., 2020). Post-infection or non-infectious autoimmune encephalitis are known to be associated with antibodies against neuronal cell-surface or synaptic proteins (Leypoldt et al., 2015). The clinical phenotype similarly includes neurological and psychiatric presentations without CSF pleocytosis, and early immunotherapy improves outcome (Leypoldt et al., 2015). In patients with recent episodes of psychosis, higher prevalence of antibodies against four coronaviruses strains are reported (Severance et al., 2011), which supports the possibility of SARS-CoV2 encephalopathy and psychosis. It is unknown if immunotherapy is required to improve neurocognitive outcome in patients with SARS-CoV2 encephalopathy.
  23 in total

Review 1.  COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2.

Authors:  Ariane Lewis; Rajan Jain; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neuroimaging       Date:  2021-06-08       Impact factor: 2.324

Review 2.  Status epilepticus and COVID-19: A systematic review.

Authors:  Fedele Dono; Bruna Nucera; Jacopo Lanzone; Giacomo Evangelista; Fabrizio Rinaldi; Rino Speranza; Serena Troisi; Lorenzo Tinti; Mirella Russo; Martina Di Pietro; Marco Onofrj; Laura Bonanni; Giovanni Assenza; Catello Vollono; Francesca Anzellotti; Francesco Brigo
Journal:  Epilepsy Behav       Date:  2021-03-17       Impact factor: 3.337

Review 3.  Cerebrospinal fluid in COVID-19: A systematic review of the literature.

Authors:  Ariane Lewis; Jennifer Frontera; Dimitris G Placantonakis; Jennifer Lighter; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neurol Sci       Date:  2021-01-10       Impact factor: 3.181

Review 4.  The three frontlines against COVID-19: Brain, Behavior, and Immunity.

Authors:  Shao-Cheng Wang; Kuan-Pin Su; Carmine M Pariante
Journal:  Brain Behav Immun       Date:  2021-02-04       Impact factor: 7.217

5.  Delirium in a pregnant woman with SARS-CoV-2 infection in India.

Authors:  Niraj N Mahajan; Rahul K Gajbhiye; Rahi R Pednekar; Madhura P Pophalkar; Shweta N Kesarwani; Aishwarya V Bhurke; Smita D Mahale
Journal:  Asian J Psychiatr       Date:  2020-12-11

6.  Autoimmune limbic encephalitis related to SARS-CoV-2 infection: Case-report and review of the literature.

Authors:  Chiara Pizzanelli; Chiara Milano; Silvia Canovetti; Enrico Tagliaferri; Francesco Turco; Stefano Verdenelli; Lorenzo Nesti; Marta Franchi; Enrica Bonanni; Francesco Menichetti; Duccio Volterrani; Mirco Cosottini; Gabriele Siciliano
Journal:  Brain Behav Immun Health       Date:  2021-01-24

Review 7.  Infectious and immune-mediated central nervous system disease in 48 COVID-19 patients.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  J Clin Neurosci       Date:  2021-06-01       Impact factor: 1.961

Review 8.  Cerebrospinal fluid findings in patients with seizure in the setting of COVID-19: A review of the literature.

Authors:  Elizabeth Carroll; Kara R Melmed; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Ariane Lewis
Journal:  Seizure       Date:  2021-05-17       Impact factor: 3.414

9.  Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories.

Authors:  Riccardo Manca; Matteo De Marco; Paul G Ince; Annalena Venneri
Journal:  Front Aging Neurosci       Date:  2021-06-03       Impact factor: 5.750

Review 10.  Infectious/parainfectious, nonvascular, nonhypoxic central nervous system disease in 48 COVID-19 patients.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.